Compare DNUT & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | ZVRA |
|---|---|---|
| Founded | 1937 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.3M | 502.7M |
| IPO Year | 2021 | 2015 |
| Metric | DNUT | ZVRA |
|---|---|---|
| Price | $3.13 | $8.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $6.22 | ★ $21.71 |
| AVG Volume (30 Days) | ★ 2.3M | 982.1K |
| Earning Date | 02-24-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | ★ $1,534,272,000.00 | $84,388,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | $0.19 | $44.19 |
| P/E Ratio | ★ N/A | $16.64 |
| Revenue Growth | N/A | ★ 244.60 |
| 52 Week Low | $2.50 | $6.19 |
| 52 Week High | $9.43 | $13.16 |
| Indicator | DNUT | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 30.33 | 41.76 |
| Support Level | $3.03 | $8.51 |
| Resistance Level | $3.31 | $9.62 |
| Average True Range (ATR) | 0.15 | 0.51 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 13.61 | 2.02 |
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.